Base de dados : MEDLINE
Pesquisa : D02.355.291.411.658 [Categoria DeCS]
Referências encontradas : 1089 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 109 ir para página                         

  1 / 1089 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29342216
[Au] Autor:Narayanaswamy VP; Giatpaiboon SA; Uhrig J; Orwin P; Wiesmann W; Baker SM; Townsend SM
[Ad] Endereço:Synedgen, Inc., Claremont, California, United States of America.
[Ti] Título:In Vitro activity of novel glycopolymer against clinical isolates of multidrug-resistant Staphylococcus aureus.
[So] Source:PLoS One;13(1):e0191522, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The incidence of multidrug-resistant (MDR) organisms, including methicillin-resistant Staphylococcus aureus (MRSA), is a serious threat to public health. Progress in developing new therapeutics is being outpaced by antibiotic resistance development, and alternative agents that rapidly permeabilize bacteria hold tremendous potential for treating MDR infections. A new class of glycopolymers includes polycationic poly-N (acetyl, arginyl) glucosamine (PAAG) is under development as an alternative to traditional antibiotic strategies to treat MRSA infections. This study demonstrates the antibacterial activity of PAAG against clinical isolates of methicillin and mupirocin-resistant Staphylococcus aureus. Multidrug-resistant S. aureus was rapidly killed by PAAG, which completely eradicated 88% (15/17) of all tested strains (6-log reduction in CFU) in ≤ 12-hours at doses that are non-toxic to mammalian cells. PAAG also sensitized all the clinical MRSA strains (17/17) to oxacillin as demonstrated by the observed reduction in the oxacillin MIC to below the antibiotic resistance breakpoint. The effect of PAAG and standard antibiotics including vancomycin, oxacillin, mupirocin and bacitracin on MRSA permeability was studied by measuring propidium iodide (PI) uptake by bacterial cells. Antimicrobial resistance studies showed that S. aureus developed resistance to PAAG at a rate slower than to mupirocin but similar to bacitracin. PAAG was observed to resensitize drug-resistant S. aureus strains sampled from passage 13 and 20 of the multi-passage resistance study, reducing MICs of mupirocin and bacitracin below their clinical sensitivity breakpoints. This class of bacterial permeabilizing glycopolymers may provide a new tool in the battle against multidrug-resistant bacteria.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Glucosamina/análogos & derivados
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Polímeros/farmacologia
Polissacarídeos/farmacologia
[Mh] Termos MeSH secundário: Antibacterianos/química
Farmacorresistência Bacteriana Múltipla
Glucosamina/química
Glucosamina/farmacologia
Glicosídeos
Seres Humanos
Técnicas In Vitro
Resistência a Meticilina
Staphylococcus aureus Resistente à Meticilina/isolamento & purificação
Staphylococcus aureus Resistente à Meticilina/metabolismo
Testes de Sensibilidade Microbiana
Mupirocina/farmacologia
Permeabilidade/efeitos dos fármacos
Polímeros/química
Polissacarídeos/química
Propídio/farmacocinética
Infecções Estafilocócicas/tratamento farmacológico
Infecções Estafilocócicas/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Glycosides); 0 (Polymers); 0 (Polysaccharides); 0 (pinocembrin 7-O-apiosyl(1-5)apiosyl(1-2)glucopyranoside); 0 (poly-N (acetyl, arginyl)glucosamine); 36015-30-2 (Propidium); D0GX863OA5 (Mupirocin); N08U5BOQ1K (Glucosamine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191522


  2 / 1089 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28686044
[Au] Autor:Bakkiyaraj D; Sritharadol R; Padmavathi AR; Nakpheng T; Srichana T
[Ad] Endereço:a Nanotec-PSU Excellence Center on Drug Delivery System, Faculty of Pharmaceutical Sciences , Prince of Songkla University , Hat Yai , Thailand.
[Ti] Título:Anti-biofilm properties of a mupirocin spray formulation against Escherichia coli wound infections.
[So] Source:Biofouling;33(7):591-600, 2017 Aug.
[Is] ISSN:1029-2454
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Mupirocin ointment is a widely used topical drug for the treatment of bacterial skin infections. However, ointments have some limitations which motivated the development of a film forming spray of mupirocin. Mupirocin spray (2%) was formulated with Eudragit E100 as a film forming agent and tested for its antibacterial and anti-biofilm activities against Escherichia coli, a skin pathogen causing wound and surgical site infections. Treatment with mupirocin spray resulted in significant antibacterial and anti-biofilm activities (inhibition and disruption) with single spray and sub-actual dose concentrations at par with the commercial ointment concentration. The spray formulation was found to be non-toxic to fibroblast cells and greatly resisted removal from the site of application upon washing, in contrast to the ointment which was significantly removed after a single wash. This is the first study to develop and evaluate a spray formulation for mupirocin that forms a stable thin film for sustained release of the drug.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Biofilmes/efeitos dos fármacos
Escherichia coli/efeitos dos fármacos
Mupirocina/farmacologia
Dermatopatias Bacterianas/tratamento farmacológico
Infecções Estafilocócicas/tratamento farmacológico
Infecção dos Ferimentos/tratamento farmacológico
[Mh] Termos MeSH secundário: Acrilatos/química
Administração Cutânea
Aerossóis
Antibacterianos/administração & dosagem
Antibacterianos/toxicidade
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Composição de Medicamentos
Escherichia coli/isolamento & purificação
Seres Humanos
Mupirocina/administração & dosagem
Mupirocina/toxicidade
Pomadas
Polímeros/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acrylates); 0 (Aerosols); 0 (Anti-Bacterial Agents); 0 (Eudragit E100); 0 (Ointments); 0 (Polymers); D0GX863OA5 (Mupirocin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE
[do] DOI:10.1080/08927014.2017.1337100


  3 / 1089 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28581830
[Au] Autor:Sritharadol R; Nakpheng T; Wan Sia Heng P; Srichana T
[Ad] Endereço:a Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences , Prince of Songkla University , Hat Yai, Songkhla , Thailand.
[Ti] Título:Development of a topical mupirocin spray for antibacterial and wound-healing applications.
[So] Source:Drug Dev Ind Pharm;43(10):1715-1728, 2017 Oct.
[Is] ISSN:1520-5762
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to develop mupirocin topical spray using Eudragit E100 as a film-forming agent for the treatment of bacterial skin infections as well as to promote wound healing. MATERIALS AND METHODS: Twenty-seven of mupirocin formulations were formulated containing Eudragit E100 and other excipients. Mupirocin spray was prepared by aerosol crimping and filling machine using HFA-134a as a propellant. The formulations were evaluated for their stability and physicochemical properties. The factorial study was applied to evaluate the effects of glycerol and PEG400 on mupirocin-loaded Eudragit E100 films. The optimized formulation was assessed of drug release, antibacterial activities and in vitro cell line studies in comparison to the ointment formulation. RESULTS AND DISCUSSION: Mupirocin sprays were formulated and optimized to obtain the formulation with excellent physicochemical and mechanical properties of the dressing film. The formulation had an excellent stability up to a year with more than 80% of mupirocin content. Mupirocin was released from the film up to 90% within 2 h. The formulation had a potent antibacterial effect against S. aureus and S. epidermidis. The formulation was safe to use as a topical formulation that had no toxicity to keratinocytes, fibroblasts and monocytes. The formulation also had an antiendotoxin effect without stimulating the production of NO and inflammatory cytokines (IL-1ß and TNF-α). CONCLUSIONS: Mupirocin topical spray was successful developed as a topical formulation and can be used instead of the ointment formulation. Animal experiments are warranted to further emphasize the safe use in the human skin.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Hidrocarbonetos Fluorados/química
Mupirocina/farmacologia
Staphylococcus aureus/efeitos dos fármacos
Staphylococcus epidermidis/efeitos dos fármacos
Fator de Necrose Tumoral alfa/farmacologia
Cicatrização/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Tópica
Animais
Antibacterianos/química
Antibacterianos/farmacologia
Química Farmacêutica
Seres Humanos
Mupirocina/administração & dosagem
Mupirocina/química
Staphylococcus aureus/química
Staphylococcus epidermidis/química
Fator de Necrose Tumoral alfa/química
Cicatrização/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Hydrocarbons, Fluorinated); 0 (Tumor Necrosis Factor-alpha); D0GX863OA5 (Mupirocin); R40P36GDK6 (apaflurane)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE
[do] DOI:10.1080/03639045.2017.1339077


  4 / 1089 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28577844
[Au] Autor:Saraswat MK; Magruder JT; Crawford TC; Gardner JM; Duquaine D; Sussman MS; Maragakis LL; Whitman GJ
[Ad] Endereço:Division of Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland.
[Ti] Título:Preoperative Staphylococcus Aureus Screening and Targeted Decolonization in Cardiac Surgery.
[So] Source:Ann Thorac Surg;104(4):1349-1356, 2017 Oct.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We assessed the impact of preoperative Staphylococcus aureus screening and targeted decolonization on the incidence of postoperative methicillin-resistant S aureus (MRSA) colonization, intensive care unit MRSA transmission, and surgical site infections in cardiac surgery patients. METHODS: We reviewed medical records for all adult patients during two periods: preintervention (January 2007 to April 2010) and intervention (January 2011 to December 2014). In the intervention period, we performed nasal screening for methicillin-sensitive S aureus and MRSA using polymerase chain reaction within 30 days of the operation. Colonized patients received intranasal mupirocin twice daily and chlorhexidine baths daily for 5 days; patients colonized with MRSA also received prophylactic vancomycin plus cefazolin with contact isolation precautions. Nasal surveillance for MRSA was performed on intensive care unit admission and weekly thereafter. Multivariable logistic regression models were constructed to determine risk factors for postoperative MRSA colonization, and surgical site infections and the impact of our screening program was assessed in these models. Poisson regression was used to assess MRSA transmission. RESULTS: Comparing 2,826 preintervention and 4,038 intervention patients, cases differed in age, diabetes mellitus, preoperative infection, preoperative length of stay, and bypass time (all p ≤ 0.03). Intervention patients had risk-adjusted reductions in MRSA colonization (odds ratio 0.53, 95% confidence interval [CI]: 0.37 to 0.76, p < 0.001), transmission (incidence rate ratio 0.29, 95% CI: 0.13 to 0.65, p = 0.002), and surgical site infections (odds ratio 0.58, 95% CI: 0.40 to 0.86, p = 0.007). Increased duration of preoperative decolonization therapy was associated with decreased postoperative MRSA colonization (odds ratio 0.73, 95% CI: 0.53 to 1.00, p = 0.05). CONCLUSIONS: Preoperative S aureus screening with targeted decolonization was associated with reduced MRSA colonization, transmission, and surgical site infections. Duration of preoperative therapy correlated with decreased frequency of postoperative MRSA colonization.
[Mh] Termos MeSH primário: Anti-Infecciosos/uso terapêutico
Procedimentos Cirúrgicos Cardíacos
Portador Sadio/diagnóstico
Clorexidina/uso terapêutico
Mupirocina/uso terapêutico
Infecções Estafilocócicas/tratamento farmacológico
Staphylococcus aureus/isolamento & purificação
Infecção da Ferida Cirúrgica/prevenção & controle
[Mh] Termos MeSH secundário: Administração Intranasal
Adulto
Idoso
Portador Sadio/tratamento farmacológico
Feminino
Seres Humanos
Modelos Logísticos
Masculino
Staphylococcus aureus Resistente à Meticilina/isolamento & purificação
Meia-Idade
Nariz/microbiologia
Infecções Estafilocócicas/prevenção & controle
Infecções Estafilocócicas/transmissão
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Infective Agents); D0GX863OA5 (Mupirocin); R4KO0DY52L (Chlorhexidine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170605
[St] Status:MEDLINE


  5 / 1089 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28516472
[Au] Autor:Liu Z; Norman G; Iheozor-Ejiofor Z; Wong JK; Crosbie EJ; Wilson P
[Ad] Endereço:Division of Nursing, Midwifery & Social Work, School of Health Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester Academic Health Science Centre, Jean McFarlane Building, Oxford Road, Manchester, UK, M13 9PL.
[Ti] Título:Nasal decontamination for the prevention of surgical site infection in Staphylococcus aureus carriers.
[So] Source:Cochrane Database Syst Rev;5:CD012462, 2017 05 18.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Surgical site infection rates in the month following surgery vary from 1% to 5%. Due to the large number of surgical procedures conducted annually, the costs of these surgical site infections (SSIs) can be considerable in financial and social terms. Nasal decontamination using antibiotics or antiseptics is performed to reduce the risk of SSIs by preventing organisms from the nasal cavity being transferred to the skin where a surgical incision will be made. Staphylococcus aureus (S aureus) colonises the nasal cavity and skin of carriers and can cause infection in open or unhealed surgical wounds. S aureus is the leading nosocomial (hospital-acquired) pathogen in hospitals worldwide. The potential effectiveness of nasal decontamination of S aureus is thought to be dependent on both the antibiotic/antiseptic used and the dose of application; however, it is unclear whether nasal decontamination actually reduces postoperative wound infection in S aureus carriers. OBJECTIVES: To assess the effects of nasal decontamination on preventing surgical site infections (SSIs) in people who are S aureus carriers undergoing surgery. SEARCH METHODS: In September 2016 we searched the Cochrane Wounds Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library), Ovid MEDLINE, Ovid MEDLINE (In-Process & Other Non-Indexed Citations), Ovid Embase, and EBSCO CINAHL Plus. We also searched three clinical trial registries and the references of included studies and relevant systematic reviews. There were no restrictions based on language, date of publication or study setting. SELECTION CRITERIA: Randomised controlled trials (RCTs) which enrolled S aureus carriers with any type of surgery and assessed the use of nasal decontamination with antiseptic/antibiotic properties were included in the review. DATA COLLECTION AND ANALYSIS: Two review authors independently performed study selection, data extraction, risk of bias assessment and GRADE assessment. MAIN RESULTS: We located two studies (291 participants) for inclusion in this review. The trials were clinically heterogeneous with differences in duration of follow-up, and nasal decontamination regimens. One study compared mupirocin (2% contained in a base of polyethylene glycol 400 and polyethylene glycol 3350) with a placebo in elective cardiac surgery patients; and one study compared Anerdian (iodine 0.45% to 0.57% (W/V), chlorhexidine acetate 0.09% to 0.11% (W/V)) with no treatment also in cardiac surgery patients. The trials reported limited outcome data on SSI, adverse events and secondary outcomes (e.g. S aureus SSI, mortality). Mupirocin compared with placeboThis study found no clear difference in SSI risk following use of mupirocin compared with placebo (1 trial, 257 participants); risk ratio (RR) 1.60, 95% confidence interval (CI) 0.79 to 3.25 based on 18/130 events in the mupirocin group and 11/127 in the control group; low-certainty evidence (downgraded twice due to imprecision). Anerdian compared with no treatmentIt is uncertain whether there is a difference in SSI risk following treatment with Anerdian compared with no treatment (1 trial, 34 participants); RR 0.89, 95% CI 0.06 to 13.08 based on 1/18 events in the Anerdian group and 1/16 in the control group; very low certainty evidence (downgraded twice due to imprecision and once due to risk of bias). AUTHORS' CONCLUSIONS: There is currently limited rigorous RCT evidence available regarding the clinical effectiveness of nasal decontamination in the prevention of SSI. This limitation is specific to the focused question our review addresses, looking at nasal decontamination as a single intervention in participants undergoing surgery who are known S aureus carriers. We were only able to identify two studies that met the inclusion criteria for this review and one of these was very small and poorly reported. The potential benefits and harms of using decontamination for the prevention of SSI in this group of people remain uncertain.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Anti-Infecciosos Locais/uso terapêutico
Procedimentos Cirúrgicos Cardíacos
Portador Sadio/tratamento farmacológico
Nariz/microbiologia
Infecções Estafilocócicas/tratamento farmacológico
Infecção da Ferida Cirúrgica/prevenção & controle
[Mh] Termos MeSH secundário: Clorexidina/uso terapêutico
Combinação de Medicamentos
Seres Humanos
Iodo/uso terapêutico
Mupirocina/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Infecções Estafilocócicas/mortalidade
Staphylococcus aureus
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-Infective Agents, Local); 0 (Drug Combinations); 9679TC07X4 (Iodine); D0GX863OA5 (Mupirocin); R4KO0DY52L (Chlorhexidine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170519
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD012462.pub2


  6 / 1089 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28390069
[Au] Autor:Campbell D; Mudge DW; Craig JC; Johnson DW; Tong A; Strippoli GF
[Ad] Endereço:Centre for Kidney Research, The Children's Hospital at Westmead, Locked Bag 4001, Westmead, NSW, Australia, 2145.
[Ti] Título:Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients.
[So] Source:Cochrane Database Syst Rev;4:CD004679, 2017 04 08.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Peritoneal dialysis (PD) is an important therapy for patients with end-stage kidney disease and is used in more than 200,000 such patients globally. However, its value is often limited by the development of infections such as peritonitis and exit-site and tunnel infections. Multiple strategies have been developed to reduce the risk of peritonitis including antibiotics, topical disinfectants to the exit site and antifungal agents. However, the effectiveness of these strategies has been variable and are based on a small number of randomised controlled trials (RCTs). The optimal preventive strategies to reduce the occurrence of peritonitis remain unclear.This is an update of a Cochrane review first published in 2004. OBJECTIVES: To evaluate the benefits and harms of antimicrobial strategies used to prevent peritonitis in PD patients. SEARCH METHODS: We searched the Cochrane Kidney and Transplant's Specialised Register to 4 October 2016 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. SELECTION CRITERIA: RCTs or quasi-RCTs in patients receiving chronic PD, which evaluated any antimicrobial agents used systemically or locally to prevent peritonitis or exit-site/tunnel infection were included. DATA COLLECTION AND ANALYSIS: Two authors independently assessed risk of bias and extracted data. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratio (RR) with 95% confidence intervals (CI). MAIN RESULTS: Thirty-nine studies, randomising 4435 patients, were included. Twenty additional studies have been included in this update. The risk of bias domains were often unclear or high; risk of bias was judged to be low in 19 (49%) studies for random sequence generation, 12 (31%) studies for allocation concealment, 22 (56%) studies for incomplete outcome reporting, and in 12 (31%) studies for selective outcome reporting. Blinding of participants and personnel was considered to be at low risk of bias in 8 (21%) and 10 studies (26%) for blinding of outcome assessors. It should be noted that blinding of participants and personnel was not possible in many of the studies because of the nature of the intervention or control treatment.The use of oral or topical antibiotic compared with placebo/no treatment, had uncertain effects on the risk of exit-site/tunnel infection (3 studies, 191 patients, low quality evidence: RR 0.45, 95% CI 0.19 to 1.04) and the risk of peritonitis (5 studies, 395 patients, low quality evidence: RR 0.82, 95% CI 0.57 to 1.19).The use of nasal antibiotic compared with placebo/no treatment had uncertain effects on the risk of exit-site/tunnel infection (3 studies, 338 patients, low quality evidence: RR 1.34, 95% CI 0.62 to 2.87) and the risk of peritonitis (3 studies, 338 patients, low quality evidence: RR 0.94, 95% CI 0.67 to 1.31).Pre/perioperative intravenous vancomycin compared with no treatment may reduce the risk of early peritonitis (1 study, 177 patients, low quality evidence: RR 0.08, 95% CI 0.01 to 0.61) but has an uncertain effect on the risk of exit-site/tunnel infection (1 study, 177 patients, low quality evidence: RR 0.36, 95% CI 0.10 to 1.32).The use of topical disinfectant compared with standard care or other active treatment (antibiotic or other disinfectant) had uncertain effects on the risk of exit-site/tunnel infection (8 studies, 973 patients, low quality evidence, RR 1.00, 95% CI 0.75 to 1.33) and the risk of peritonitis (6 studies, 853 patients, low quality evidence: RR 0.83, 95% CI 0.65 to 1.06).Antifungal prophylaxis with oral nystatin/fluconazole compared with placebo/no treatment may reduce the risk of fungal peritonitis occurring after a patient has had an antibiotic course (2 studies, 817 patients, low quality evidence: RR 0.28, 95% CI 0.12 to 0.63).No intervention reduced the risk of catheter removal or replacement. Most of the available studies were small and of suboptimal quality. Only six studies enrolled 200 or more patients. AUTHORS' CONCLUSIONS: In this update, we identified limited data from RCTs and quasi-RCTs which evaluated strategies to prevent peritonitis and exit-site/tunnel infections. This review demonstrates that pre/peri-operative intravenous vancomycin may reduce the risk of early peritonitis and that antifungal prophylaxis with oral nystatin or fluconazole reduces the risk of fungal peritonitis following an antibiotic course. However, no other antimicrobial interventions have proven efficacy. In particular, the use of nasal antibiotic to eradicate Staphylococcus aureus, had an uncertain effect on the risk of peritonitis and raises questions about the usefulness of this approach. Given the large number of patients on PD and the importance of peritonitis, the lack of adequately powered and high quality RCTs to inform decision making about strategies to prevent peritonitis is striking.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Antibioticoprofilaxia
Infecções Relacionadas a Cateter/prevenção & controle
Diálise Peritoneal/efeitos adversos
Peritonite/prevenção & controle
[Mh] Termos MeSH secundário: Administração Intranasal
Administração Tópica
Antibacterianos/administração & dosagem
Anti-Infecciosos Locais/administração & dosagem
Anti-Infecciosos Locais/uso terapêutico
Antifúngicos/administração & dosagem
Antifúngicos/uso terapêutico
Infecções Relacionadas a Cateter/epidemiologia
Remoção de Dispositivo/efeitos adversos
Seres Humanos
Injeções Intravenosas
Mupirocina/administração & dosagem
Mupirocina/uso terapêutico
Micoses/prevenção & controle
Peritonite/epidemiologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Vancomicina/administração & dosagem
Vancomicina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-Infective Agents, Local); 0 (Antifungal Agents); 6Q205EH1VU (Vancomycin); D0GX863OA5 (Mupirocin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170801
[Lr] Data última revisão:
170801
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170409
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD004679.pub3


  7 / 1089 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28301626
[Au] Autor:Lee MA; Cohen PR
[Ti] Título:Zoon Balanitis Revisited: Report of Balanitis Circumscripta Plasmacellularis Resolving With Topical Mupirocin Ointment Monotherapy.
[So] Source:J Drugs Dermatol;16(3):285-287, 2017 Mar 01.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:

INTRODUCTION: Zoon balanitis is an idiopathic benign inflammatory condition of the glans penis and prepuce. A patient with biopsy confirmed diagnosis of Zoon balanitis who was successfully treated with topical mupirocin ointment monotherapy is described.

METHOD: A search using PubMed database was performed using the following terms: Zoon balanitis (cases, diagnosis, treatment of), balanitis circumscripta plasmacellularis, and mupirocin. Relevant papers and their reference citations were reviewed and evaluated.

RESULTS: The gold standard of treatment for Zoon balanitis has previously been circumcision. More recently, topical calcineurin inhibitors have been shown to be effective. Our patient had successful resolution of his Zoon balanitis after 3 months of mupirocin ointment monotherapy.

DISCUSSION: Zoon balanitis is a benign inflammatory dermatosis. Previous successful treatment modalities include circumcision, phototherapy, laser therapy, and topical calcineurin inhibitors. Topical mupirocin ointment twice daily resulted in resolution of Zoon balanitis in our patient. Additional evaluation of mupirocin ointment as a therapeutic agent should be considered as a potential first-line therapy in patients with Zoon balanitis.

J Drugs Dermatol. 2017;16(3):285-287.

.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Balanite (Inflamação)/diagnóstico
Balanite (Inflamação)/terapia
Mupirocina/uso terapêutico
[Mh] Termos MeSH secundário: Antibacterianos/administração & dosagem
Anti-Infecciosos Locais/uso terapêutico
Balanite (Inflamação)/etiologia
Balanite (Inflamação)/patologia
Biópsia
Inibidores de Calcineurina/uso terapêutico
Circuncisão Masculina
Clotrimazol/administração & dosagem
Clotrimazol/uso terapêutico
Diagnóstico Diferencial
Seres Humanos
Masculino
Meia-Idade
Mupirocina/administração & dosagem
Pomadas
Pênis/patologia
Fototerapia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-Infective Agents, Local); 0 (Calcineurin Inhibitors); 0 (Ointments); D0GX863OA5 (Mupirocin); G07GZ97H65 (Clotrimazole)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE


  8 / 1089 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28215714
[Au] Autor:Roghmann MC; Lydecker AD; Langenberg P; Mongodin EF; Johnson JK
[Ad] Endereço:Geriatrics Research Education and Clinical Center, VA Maryland Health Care System, Baltimore, MD, 21201; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, 21201. Electronic address: mroghman@epi.umaryland.edu.
[Ti] Título:Microbiological effect of mupirocin and chlorhexidine for Staphylococcus aureus decolonization in community and nursing home based adults.
[So] Source:Diagn Microbiol Infect Dis;88(1):53-57, 2017 May.
[Is] ISSN:1879-0070
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare the presence of Staphylococcus aureus and pathogenic Gram-negative rods (GNR) in the anterior nares, posterior pharynx and three skin sites in community-based adults and nursing home-based adults before and after treatment with nasal mupirocin and topical chlorhexidine. METHODS: S. aureus-colonized adults were recruited from the community (n=26) and from nursing homes (n=8). Eligible participants were cultured for S. aureus and GNR during two study visits and then received intranasal mupirocin and topical chlorhexidine for 5days, with a 2-month follow-up period. RESULTS: After decolonization, we found sustained decreases of S. aureus colonization in nose, throat and skin sites over 4-8weeks in both populations. Intranasal mupirocin did not increase GNR colonization in nose or throat. Chlorhexidine did not decrease GNR colonization in skin sites. CONCLUSIONS: Decolonization with mupirocin and chlorhexidine leads to a sustained effect on S. aureus colonization without affecting GNR colonization.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Portador Sadio/tratamento farmacológico
Portador Sadio/microbiologia
Clorexidina/administração & dosagem
Mupirocina/administração & dosagem
Infecções Estafilocócicas/tratamento farmacológico
Staphylococcus aureus/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Idoso
Idoso de 80 Anos ou mais
Infecções Comunitárias Adquiridas/tratamento farmacológico
Infecções Comunitárias Adquiridas/microbiologia
Infecção Hospitalar/tratamento farmacológico
Infecção Hospitalar/microbiologia
Feminino
Infecções por Bactérias Gram-Negativas/microbiologia
Bacilos Gram-Positivos Asporogênicos/efeitos dos fármacos
Bacilos Gram-Positivos Asporogênicos/isolamento & purificação
Seres Humanos
Masculino
Meia-Idade
Nariz/microbiologia
Casas de Saúde
Faringe/microbiologia
Estudos Prospectivos
Pele/microbiologia
Infecções Estafilocócicas/microbiologia
Staphylococcus aureus/isolamento & purificação
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); D0GX863OA5 (Mupirocin); R4KO0DY52L (Chlorhexidine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170221
[St] Status:MEDLINE


  9 / 1089 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28115345
[Au] Autor:Kudrin P; Varik V; Oliveira SR; Beljantseva J; Del Peso Santos T; Dzhygyr I; Rejman D; Cava F; Tenson T; Hauryliuk V
[Ad] Endereço:University of Tartu, Institute of Technology, Tartu, Estonia.
[Ti] Título:Subinhibitory Concentrations of Bacteriostatic Antibiotics Induce -Dependent and -Independent Tolerance to ß-Lactams.
[So] Source:Antimicrob Agents Chemother;61(4), 2017 Apr.
[Is] ISSN:1098-6596
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The nucleotide (p)ppGpp is a key regulator of bacterial metabolism, growth, stress tolerance, and virulence. During amino acid starvation, the (p)ppGpp synthetase RelA is activated by deacylated tRNA in the ribosomal A-site. An increase in (p)ppGpp is believed to drive the formation of antibiotic-tolerant persister cells, prompting the development of strategies to inhibit (p)ppGpp synthesis. We show that in a biochemical system from purified components, the antibiotic thiostrepton efficiently inhibits RelA activation by the A-site tRNA. In bacterial cultures, the ribosomal inhibitors thiostrepton, chloramphenicol, and tetracycline all efficiently abolish accumulation of (p)ppGpp induced by the Ile-tRNA synthetase inhibitor mupirocin. This abolishment, however, does not reduce the persister level. In contrast, the combination of dihydrofolate reductase inhibitor trimethoprim with mupirocin, tetracycline, or chloramphenicol leads to ampicillin tolerance. The effect is independent of RelA functionality, specific to ß-lactams, and not observed with the fluoroquinolone norfloxacin. These results refine our understanding of (p)ppGpp's role in antibiotic tolerance and persistence and demonstrate unexpected drug interactions that lead to tolerance to bactericidal antibiotics.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Tolerância a Medicamentos
Guanosina Tetrafosfato/análogos & derivados
Ligases/genética
Tioestreptona/farmacologia
beta-Lactamas/farmacologia
[Mh] Termos MeSH secundário: Cloranfenicol/farmacologia
Interações Medicamentosas
Escherichia coli/química
Escherichia coli/genética
Escherichia coli/metabolismo
Guanosina Tetrafosfato/metabolismo
Isoleucina-tRNA Ligase/genética
Ligases/antagonistas & inibidores
Ligases/metabolismo
Mupirocina/farmacologia
Biossíntese de Proteínas/efeitos dos fármacos
RNA de Transferência/genética
RNA de Transferência/metabolismo
Ribossomos/efeitos dos fármacos
Ribossomos/metabolismo
Frações Subcelulares/química
Frações Subcelulares/efeitos dos fármacos
Frações Subcelulares/metabolismo
Tetraciclina/farmacologia
Tetra-Hidrofolato Desidrogenase/genética
Tetra-Hidrofolato Desidrogenase/metabolismo
Trimetoprima/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (beta-Lactams); 33503-72-9 (Guanosine Tetraphosphate); 56878-12-7 (adenosine 5',5'''-triphosphoguanosine-3'''-diphosphate); 66974FR9Q1 (Chloramphenicol); 9014-25-9 (RNA, Transfer); AN164J8Y0X (Trimethoprim); D0GX863OA5 (Mupirocin); EC 1.5.1.3 (Tetrahydrofolate Dehydrogenase); EC 6.- (Ligases); EC 6.- (guanosine 3',5'-polyphosphate synthetases); EC 6.1.1.5 (Isoleucine-tRNA Ligase); F8VB5M810T (Tetracycline); HR4S203Y18 (Thiostrepton)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170125
[St] Status:MEDLINE


  10 / 1089 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28081909
[Au] Autor:Lefebvre J; Buffet-Bataillon S; Henaux PL; Riffaud L; Morandi X; Haegelen C
[Ad] Endereço:Department of Neurosurgery, Pontchaillou University Hospital, Rennes, France. Electronic address: Jean.LEFEBVRE@chu-rennes.fr.
[Ti] Título:Staphylococcus aureus screening and decolonization reduces the risk of surgical site infections in patients undergoing deep brain stimulation surgery.
[So] Source:J Hosp Infect;95(2):144-147, 2017 Feb.
[Is] ISSN:1532-2939
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In a controlled before-and-after study in a single centre, it was aimed to determine whether identification of Staphylococcus aureus nasal carriers followed by nasal mupirocin ointment and chlorhexidine soap reduced surgical site infections (SSIs) among 182 patients undergoing deep brain stimulation. In all, 119 patients were included in the control group and 63 in the screening group. There was a significant SSI decrease from 10.9% to 1.6% between the two groups (P<0.04; relative risk: 0.13; 95% confidence interval: 0.003-0.922). There were eight SSIs involving S. aureus in the control group, none in the screening group. No specific risk factors for SSI were identified.
[Mh] Termos MeSH primário: Portador Sadio/diagnóstico
Estimulação Encefálica Profunda
Controle de Infecções/métodos
Cuidados Pré-Operatórios/métodos
Infecções Estafilocócicas/diagnóstico
Infecções Estafilocócicas/prevenção & controle
Infecção da Ferida Cirúrgica/prevenção & controle
[Mh] Termos MeSH secundário: Adulto
Idoso
Portador Sadio/tratamento farmacológico
Clorexidina/administração & dosagem
Estudos Controlados Antes e Depois
Desinfetantes/administração & dosagem
Feminino
Seres Humanos
Masculino
Programas de Rastreamento/utilização
Meia-Idade
Mupirocina/administração & dosagem
Sabões/administração & dosagem
Infecções Estafilocócicas/tratamento farmacológico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Disinfectants); 0 (Soaps); D0GX863OA5 (Mupirocin); R4KO0DY52L (Chlorhexidine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170302
[Lr] Data última revisão:
170302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170114
[St] Status:MEDLINE



página 1 de 109 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde